Effects of gene polymorphism on toxicity and efficacy of Platinum-based drugs in Han Chinese patients with solid carcinoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-RCS-12002860

Enrollment

Unknown

Registered

2012-12-24

Start date

2009-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

1:platinum-based drugs

Eligibility

Sex/Gender

Male

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: clinically diagnosed solid tumor such as lung cancer, colorectal cancer,head and neck neoplasm and breast cancer; Chemothrapy with platinum-based drugs

Exclusion criteria

Exclusion criteria: Brain metastasis; cardiovascular disease; infection

Design outcomes

Primary

Measure	Time frame
liver function;renal function;blood routine examination;	—

Countries

China

Contacts

Public ContactWei Zhang

yjsd2003@163.com+86 13973168774

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026